Cargando…

Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data

OBJECTIVE: Although temozolomide has been extensively used to treat various tumors, there is a lack of large-cohort studies on temozolomide’s toxicity profile. The toxicity profiles and associated factors in patients treated with temozolomide-containing regimens were analyzed. PATIENTS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Chen, Wang, Xiong, Diao, Changdong, Zhu, Haixia, Yuan, Qi, Liu, Jinmei, Li, Shijun, Gu, Ming, Zhang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146745/ https://www.ncbi.nlm.nih.gov/pubmed/34045849 http://dx.doi.org/10.2147/DDDT.S305792

Ejemplares similares

Optimal dynamic regimens with artificial intelligence: The case of temozolomide
por: Houy, Nicolas, et al.
Publicado: (2018)

Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated Infections
por: Chao, Chien-Ming, et al.
Publicado: (2016)

Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma
por: Munhoz, Rodrigo Ramella, et al.
Publicado: (2013)

Tumor Treating Fields Suppression of Ciliogenesis Enhances Temozolomide Toxicity
por: Shi, Ping, et al.
Publicado: (2022)

Evaluating antibiotic regimens for streptococcal toxic shock syndrome in children
por: Zhang, Haixia, et al.
Publicado: (2023)

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
por: Ünal, Çağlar, et al.
Publicado: (2023)

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs
por: Melchardt, Thomas, et al.
Publicado: (2014)

Characterization of rifampin-resistant Staphylococcus aureus nasal carriage in patients receiving rifampin-containing regimens for tuberculosis
por: Huang, Yu-Tsung, et al.
Publicado: (2018)

1884. Clinical Outcomes Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline or Delamanid Containing Regimens
por: Kempker, Russell R, et al.
Publicado: (2019)

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
por: Ju, Hee Young, et al.
Publicado: (2022)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
por: Hsieh, Meng-Che, et al.
Publicado: (2022)

Antitumor effect of fibrin glue containing temozolomide against malignant glioma
por: Anai, Shigeo, et al.
Publicado: (2014)

Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation
por: Niewald, Marcus, et al.
Publicado: (2011)

Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea
por: Bae, So Hyun, et al.
Publicado: (2014)

Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen
por: Aurpibul, Linda, et al.
Publicado: (2019)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
por: Ataca Atilla, Pınar, et al.
Publicado: (2019)

DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma
por: Galbán, Stefanie, et al.
Publicado: (2012)

Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen
por: Lacin, Sahin, et al.
Publicado: (2015)

Role of Temozolomide Regimen on Survival Outcomes in Molecularly Stratified WHO Grade II Gliomas: A Systematic Review
por: Ghaffari-Rafi, Arash, et al.
Publicado: (2021)

Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide
por: Chai, Kit Man, et al.
Publicado: (2014)

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy
por: Wan, Yanzhi, et al.
Publicado: (2023)

Regulating thermochemical redox temperature via oxygen defect engineering for protection of solar molten salt receivers
por: Yuan, Peng, et al.
Publicado: (2021)

Wellens syndrome during chemotherapy for cholangiocarcinoma: A case report of cardiovascular toxicity associated with gemcitabine-containing regimen
por: Liang, Xufei, et al.
Publicado: (2023)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma
por: Lu, Chenfei, et al.
Publicado: (2020)

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
por: Rhee, Soo-Yon, et al.
Publicado: (2017)

Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine
por: Nelson, Richard E., et al.
Publicado: (2018)

Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens
por: Budak, Maral, et al.
Publicado: (2023)

Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy
por: Chu, Sheng-Hua, et al.
Publicado: (2013)

Herpetic esophagitis following bendamustine-containing regimen
por: Yamane, Hiromichi, et al.
Publicado: (2016)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Leucine-rich repeat containing 4 act as an autophagy inhibitor that restores sensitivity of glioblastoma to temozolomide
por: Feng, Jianbo, et al.
Publicado: (2020)

Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study
por: Echeverría, Patricia, et al.
Publicado: (2014)

Toxicity and Outcome of Radiotherapy with Concomitant and Adjuvant Temozolomide in Elderly Patients with Glioblastoma: A Retrospective Study
por: SAITO, Kuniaki, et al.
Publicado: (2014)

Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles
por: Tian, Xin-Hua, et al.
Publicado: (2011)

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas
por: Lamb, Lawrence S., et al.
Publicado: (2021)

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma
por: Shi, Hui, et al.
Publicado: (2020)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Temozolomide-Induced Myelodysplasia
por: Natelson, Ethan A., et al.
Publicado: (2010)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
por: Li, Jinpeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_57kenn28o5kca5777tbgvdm5hs